SPH3643: A novel cyclin‐dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood‐brain barrier permeability-Reference-Cited by-同舟云学术

SPH3643: A novel cyclin‐dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood‐brain barrier permeability

Published:2020-03-24 Issue:5 Volume:111 Page:1761-1773
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Liao XueMei¹^ORCID,Hong Yuan¹,Mao Yu¹,Chen Na¹,Wang Qian¹,Wang Zhe¹,Zhang LeDuo¹,Wang Li¹,Shi Chen¹,Shi WeiJun¹,Ge Hui¹,Li AnDi¹,Li Xin²,Xia GuangXin¹,Liu YanJun¹

Affiliation:

1. Central Research Institute Shanghai Pharmaceuticals Holding Co., Ltd. Shanghai China

2. Shanghai Pharma Biotherapeutics USA Inc. San Diego California

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14367

Reference38 articles.

1. Hallmarks of Cancer: The Next Generation

2. Differential Regulation of Retinoblastoma Tumor Suppressor Protein by G 1 Cyclin-Dependent Kinase Complexes In Vivo

3. The p16‐cyclin D/Cdk4‐pRb pathway as a functional unit frequently altered in melanoma pathogenesis;Bartkova J;Cancer Res,1996

4. Treating cancer with selective CDK4/6 inhibitors

5. Cdk Phosphorylation Triggers Sequential Intramolecular Interactions that Progressively Block Rb Functions as Cells Move through G1

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor biomarkers for diagnosis, prognosis and targeted therapy;Signal Transduction and Targeted Therapy;2024-05-20

2. Ultrasmall iron oxide nanoparticles with MRgFUS for enhanced magnetic resonance imaging of orthotopic glioblastoma;Journal of Materials Chemistry B;2024

3. Super-enhancers complexes zoom in transcription in cancer;Journal of Experimental & Clinical Cancer Research;2023-07-28

4. The Oncogenic Role of Cyclin-Dependent Kinase Inhibitor 2C in Lower-Grade Glioma;Journal of Molecular Neuroscience;2023-05-24

5. The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance;Cancers;2022-11-01